Provided by Tiger Fintech (Singapore) Pte. Ltd.

Iovance Biotherapeutics, Inc.

2.05
+0.250013.89%
Post-market: 2.04-0.0007-0.03%19:59 EDT
Volume:20.62M
Turnover:40.99M
Market Cap:684.57M
PE:-1.66
High:2.05
Open:1.81
Low:1.81
Close:1.80
Loading ...

Chief Commercial Officer Daniel Gordon Kirby Acquires Common Shares of Iovance Biotherapeutics Inc

Reuters
·
Yesterday

Goldman Sachs Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)

TIPRANKS
·
03 Jun

Iovance Biotherapeutics (IOVA) Receives a Hold from Citizens JMP

TIPRANKS
·
03 Jun

Iovance Biotherapeutics announces publication of five-year analysis of Amtagvi

TIPRANKS
·
02 Jun

Iovance Biotherapeutics (IOVA) Receives a Buy from Barclays

TIPRANKS
·
02 Jun

Wells Fargo Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)

TIPRANKS
·
23 May

Iovance Biotherapeutics announces five-year results of Amtagvi in melanoma

TIPRANKS
·
23 May

BRIEF-Iovance Announces Five-Year Results Of Amtagvi® (Lifileucel) In Patients With Advanced Melanoma At Asco Annual Meeting

Reuters
·
23 May

Iovance Announces Five-Year Results of Amtagvi® (Lifileucel) in Patients With Advanced Melanoma at Asco Annual Meeting

THOMSON REUTERS
·
23 May

Iovance Biotherapeutics Inc: One-Time Amtagvi Treatment Demonstrated Durable Responses and a Five-Year Overall Survival Rate of 20%

THOMSON REUTERS
·
23 May

BRIEF-Iovance Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
17 May

Iovance Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
17 May

Frederick G. Vogt, Interim CEO & General Counsel, Reports Acquisition of Common Shares in Iovance Biotherapeutics Inc

Reuters
·
17 May

BUZZ-UBS downgrades Iovance on sluggish uptake of skin cancer drug

Reuters
·
17 May

UBS Downgrades Iovance Biotherapeutics to Neutral From Buy, Adjusts Price Target to $2 From $17

MT Newswires Live
·
16 May

Iovance Biotherapeutics Cut to Neutral From Buy by UBS

Dow Jones
·
16 May

Iovance Biotherapeutics downgraded to Neutral from Buy at UBS

TIPRANKS
·
16 May

Iovance Biotherapeutics Q1 Revenue USD 49.3 Million

THOMSON REUTERS
·
14 May

Iovance Biotherapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
12 May

Truist Downgrades Iovance Biotherapeutics to Hold From Buy, After Q1 Sales Miss, Guidance Cut

MT Newswires Live
·
12 May